Latest news with #Immunovant
Business Wire
5 days ago
- Business
- Business Wire
IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc.
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--The law firm of Kahn Swick & Foti, LLC ('KSF') has commenced an investigation into Immunovant, Inc. (NasdaqGS: IMVT) ('Immunovant'). KSF is investigating whether Immunovant's officers and/or directors breached their fiduciary duties or otherwise violated state or federal laws. If you hold shares of Immunovant, Inc. (NasdaqGS: IMVT), we urge you to contact KSF to discuss your legal rights, without obligation or cost to you, by calling KSF toll-free at 1-833-938-0905, or by e-mailing KSF Managing Partner, Lewis Kahn, ( or visit to learn more. About Kahn Swick & Foti, LLC KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, New Jersey, and a representative office in Luxembourg. TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services To learn more about KSF, you may visit
Yahoo
16-07-2025
- Business
- Yahoo
Goldman Sachs Resumes Coverage of Immunovant (IMVT) with a Hold Rating
Immunovant, Inc. (NASDAQ:IMVT) is one of the best oversold NASDAQ stocks to buy now. On July 10, Goldman Sachs analyst Corinne Johnson resumed coverage of Immunovant, Inc. (NASDAQ:IMVT) with a Hold rating and set a price target of $18.00. A closeup of a scientist working with a microscope in a biotech laboratory. The analyst supported the Neutral rating by stating that it sees limited downside to Immunovant, Inc. (NASDAQ:IMVT), and that a challenging regulatory backdrop also exists for the company, necessitating a cautious outlook. Immunovant, Inc. (NASDAQ:IMVT) has approximately $714 million in cash and cash equivalents as of March 31, which management declared provides runway for announced indications through GD readout anticipated in 2027. Immunovant, Inc. (NASDAQ:IMVT) develops treatments for autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402. Both are novel antibodies targeting the neonatal fragment crystallizable receptor (FcRn). While we acknowledge the potential of IMVT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
06-07-2025
- Business
- Yahoo
LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT
Immunovant, Inc. (NASDAQ:IMVT) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 26, Sam Slutsky, an analyst from LifeSci Capital, maintained a Buy rating on Immunovant, Inc. (NASDAQ:IMVT), keeping the associated price target at $50. He based the rating on the notable market opportunity for the company's IMVT-1402 for the treatment of Graves' disease, which is a leading cause of hyperthyroidism and has considerable unmet medical need. A closeup of a scientist working with a microscope in a biotech laboratory. The disease impacts around a million patients in the US, and current treatments typically render a majority of patients uncontrolled or intolerant. Since alternative therapies for the disease also have considerable drawbacks, the analyst reasoned that IMVT-1402 has potential as a novel, disease-modifying therapy. It reduces pathogenic IgG autoantibodies to target the disease's root cause, and positive proof-of-concept data from a first-generation anti-FcRn supports the therapy's efficacy. The analyst further reasoned that feedback from key opinion leaders highlights the significant need and demand for such targeted treatments, painting a positive picture for Immunovant, Inc. (NASDAQ:IMVT). Apart from IMVT-1402's dual effects in Graves' disease and thyroid eye disease, the company's ongoing trials further support the optimistic rating. Immunovant, Inc. (NASDAQ:IMVT) develops treatments for autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402. Both are novel antibodies targeting the neonatal fragment crystallizable receptor (FcRn). While we acknowledge the potential of IMVT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Globe and Mail
18-06-2025
- Business
- Globe and Mail
Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen Research & Development, LLC
The Key Myasthenia Gravis Companies in the market include - Hoffmann-La Roche, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Argenx-Halozyme Therapeutics, Horizon Therapeutics, DAS Therapeutics, Chugai Pharmaceutical, Inc., Alexion, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Inc., and others. DelveInsight's 'Myasthenia Gravis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Myasthenia Gravis, historical and forecasted epidemiology as well as the Myasthenia Gravis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. Some of the key facts of the Myasthenia Gravis Market Report: Among the 7MM countries the Myasthenia Gravis market size was valued approximately USD 3,880 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034) In April 2025, Impressive findings from the Phase 3 clinical trial (NCT05737160) evaluating the safety and effectiveness of Telitacicept (also known as RC18; brand name: 泰爱®) in individuals with generalized myasthenia gravis (gMG) were presented during the Late-Breaking Science Session at the 2025 American Academy of Neurology (AAN) Annual Meeting. In March 2025, Immunovant has opted not to seek regulatory approval for its myasthenia gravis (MG) therapy, batoclimab, even though the Phase III trial achieved its primary goal of reducing disease symptoms. Instead, the company plans to use the trial data to support the advancement of its alternative candidate, IMVT-1402. The Phase III randomized study (NCT05403541) evaluated the effects of weekly or bi-weekly batoclimab dosing in acetylcholine receptor antibody-positive (AChR+) patients, measuring improvements through the Myasthenia Gravis Activities of Daily Living (MG-ADL) score over 12 weeks. In December 2024, Cartesian Therapeutics has shared updated efficacy and safety results from its Phase IIb trial evaluating Descartes-08, an mRNA cell therapy candidate for generalized myasthenia gravis (MG). The findings demonstrated durable responses at 12 months. This open-label, double-blind, placebo-controlled, crossover study (NCT06038474) enrolled 36 symptomatic patients who had previously undergone extensive treatment. Participants were divided evenly, with one group receiving a placebo and the other receiving Descartes-08. Both groups underwent six weekly outpatient infusions, administered without the need for prior chemotherapy-based preconditioning. In October 2024, Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune disorders, announced plans to present findings from its Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis (MG). The data will be shared at the 2024 Myasthenia Gravis Foundation of America (MGFA) Scientific Session, held during the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting. The combined myasthenia gravis market size in the European Union's four largest economies and the United Kingdom was approximately USD 950 million in 2023. This figure is expected to increase over the forecast period from 2024 to 2034. In June 2024, Johnson & Johnson (NYSE: JNJ) has announced encouraging outcomes from the Phase 3 Vivacity-MG3 trial of nipocalimab in patients with generalized myasthenia gravis (gMG). The trial demonstrated that patients receiving nipocalimab alongside standard of care (SOC) showed significant improvement in the MG-ADL score over 24 weeks compared to those on placebo plus SOC, meeting the primary endpoint. These findings are part of eight abstracts Johnson & Johnson will present at the 2024 European Academy of Neurology (EAN) Congress. Additionally, the data will be included in regulatory submissions later this year. In January 2024, Johnson & Johnson reported the headline findings from the critical Phase III VIVACITY trial of nipocalimab in adults with generalized myasthenia gravis (gMG). In this Phase III study, nipocalimab met its primary goal, demonstrating a statistically significant decrease in MG-ADL score from baseline during weeks 22 to 24 compared to placebo (PBO). According to DelveInsight's evaluation in 2023, the seven major markets (7MM) had an estimated 297,000 diagnosed prevalent instances of myasthenia gravis, with an expected upward trajectory in these cases anticipated during the forecast period from 2024 to 2034. In 2023, the United States had the largest number of diagnosed prevalent cases of myasthenia gravis among the seven major markets (7MM), totaling approximately 133,000 cases. It is projected that these figures will increase during the forecast period from 2024 to 2034. In 2023, myasthenia gravis affected 48% of males and 52% of females across the seven major markets (7MM). In the United States, there were approximately 66,000 cases among males and around 67,000 cases among females in 2023. These gender-specific incidences are projected to increase during the forecast period from 2024 to 2034. Emerging treatments for myasthenia gravis like Nipocalimab, Batoclimab, Descartes-08, ENSPRYNG (satralizumab), and others hold promise to substantially impact the market size of myasthenia gravis in a positive direction. Key Myasthenia Gravis Companies: Hoffmann-La Roche, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Argenx-Halozyme Therapeutics, Horizon Therapeutics, DAS Therapeutics, Chugai Pharmaceutical, Inc., Alexion, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Inc., and others Key Myasthenia Gravis Therapies: Hoffmann-La Roche, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Argenx-Halozyme Therapeutics, Horizon Therapeutics, DAS Therapeutics, Chugai Pharmaceutical, Inc., Alexion, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Inc., and others The Myasthenia Gravis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Myasthenia Gravis pipeline products will significantly revolutionize the Myasthenia Gravis market dynamics. Myasthenia Gravis Overview Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by weakness and fatigue of voluntary muscles. It occurs when the body's immune system mistakenly attacks and damages the communication between nerve cells and muscles, specifically at the neuromuscular junction. Myasthenia Gravis Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Myasthenia Gravis Epidemiology Segmentation: The Myasthenia Gravis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Prevalence of Myasthenia Gravis Prevalent Cases of Myasthenia Gravis by severity Gender-specific Prevalence of Myasthenia Gravis Diagnosed Cases of Episodic and Chronic Myasthenia Gravis Download the report to understand which factors are driving Myasthenia Gravis epidemiology trends @ Myasthenia Gravis Epidemiology Forecast Myasthenia Gravis Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Myasthenia Gravis market or expected to get launched during the study period. The analysis covers Myasthenia Gravis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Myasthenia Gravis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Myasthenia Gravis Therapies and Key Companies Myasthenia Gravis Market Strengths The growing prevalence of myasthenia gravis (MG) and the geriatric population offers a stable market demand for treatments and therapies. Myasthenia gravis treatments may qualify for orphan drug status, offering regulatory incentives, such as extended market exclusivity and tax benefits. Myasthenia Gravis Market Opportunities Potential for developing new, more effective therapies, such as gene therapy or targeted biologics, could address unmet medical needs. Improved diagnostic techniques using clear biomarkers and an increase in awareness will likely lead to a diagnosis of more patients, expanding the market. Scope of the Myasthenia Gravis Market Report Study Period: 2020-2034 Coverage: 7MM Countries Key Myasthenia Gravis Companies: Hoffmann-La Roche, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Argenx-Halozyme Therapeutics, Horizon Therapeutics, DAS Therapeutics, Chugai Pharmaceutical, Inc., Alexion, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Inc., and others Key Myasthenia Gravis Therapies: Hoffmann-La Roche, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Argenx-Halozyme Therapeutics, Horizon Therapeutics, DAS Therapeutics, Chugai Pharmaceutical, Inc., Alexion, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Inc., and others Myasthenia Gravis Therapeutic Assessment: Myasthenia Gravis current marketed and Myasthenia Gravis emerging therapies Myasthenia Gravis Market Dynamics: Myasthenia Gravis market drivers and Myasthenia Gravis market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Myasthenia Gravis Unmet Needs, KOL's views, Analyst's views, Myasthenia Gravis Market Access and Reimbursement Table of Contents 1. Myasthenia Gravis Market Report Introduction 2. Executive Summary for Myasthenia Gravis 3. SWOT analysis of Myasthenia Gravis 4. Myasthenia Gravis Patient Share (%) Overview at a Glance 5. Myasthenia Gravis Market Overview at a Glance 6. Myasthenia Gravis Disease Background and Overview 7. Myasthenia Gravis Epidemiology and Patient Population 8. Country-Specific Patient Population of Myasthenia Gravis 9. Myasthenia Gravis Current Treatment and Medical Practices 10. Myasthenia Gravis Unmet Needs 11. Myasthenia Gravis Emerging Therapies 12. Myasthenia Gravis Market Outlook 13. Country-Wise Myasthenia Gravis Market Analysis (2020-2034) 14. Myasthenia Gravis Market Access and Reimbursement of Therapies 15. Myasthenia Gravis Market Drivers 16. Myasthenia Gravis Market Barriers 17. Myasthenia Gravis Appendix 18. Myasthenia Gravis Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Yahoo
30-05-2025
- Business
- Yahoo
IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus
Immunovant, Inc. IMVT reported fourth-quarter fiscal 2025 net loss of 64 cents per share, narrower than the Zacks Consensus Estimate of a loss of 72 cents. The reported figure is wider than the year-ago quarter's loss of 52 cents per share. Currently, Immunovant does not have any approved products in its portfolio. As a result, it has yet to generate revenues. The stock gained 5.6% following the better-than-expected earnings results. (See the Zacks Earnings Calendar to stay ahead of market-making news.) Year to date, IMVT shares have plunged 39.9% compared with the industry's 3.5% decline. Image Source: Zacks Investment Research Research and development expenses totaled $93.7 million, up 42% from the year-ago quarter's figure. The uptick can be attributed to activities related to the clinical studies of IMVT-1402, including contract manufacturing costs for drug substance and increased personnel-related expenses. General and administrative expenses amounted to $20.2 million, up 36% year over year. The rise was primarily due to an increase in personnel-related expenses, legal and other professional fees, along with information technology and market research costs. As of March 31, 2025, Immunovant had a cash balance of $714 million compared with $374.7 million as of Dec. 31, 2024. Immunovant expects the extended cash runway to fund operations through 2027. Immunovant reported a loss of $2.73 per share for fiscal 2025, which matched the Zacks Consensus Estimate. The company had incurred a loss of $1.88 per share in the previous fiscal year. Immunovant has designated IMVT-1402, a next-generation FcRn inhibitor, as its lead asset going forward, given its broad potential across multiple indications. The company is on track to initiate clinical studies in a total of 10 indications for IMVT-1402 by March 31, 2026. The company expects to achieve financial efficiencies in its IMVT-1402 development program by leveraging the data already available from batoclimab studies. Currently, Immunovant is developing IMVT-1402 for six announced indications: Graves' disease (GD), difficult-to-treat rheumatoid arthritis (D2T RA), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), Sjögren's disease (SjD) and cutaneous lupus erythematosus (CLE). Potentially registrational studies for IMVT-1402 in both MG and CIDP are currently enrolling patients. The company has also initiated its first potentially registrational study of IMVT-1402 for adult patients with GD who are hyperthyroid despite antithyroid drug treatment. It is looking to initiate a second potentially registrational study of IMVT-1402 for GD in the summer of 2025. In March, Immunovant initiated a potentially registrational study of IMVT-1402 (600 mg) in adult patients with ACPA-positive D2T RA, aiming to achieve deeper ACPA reduction for improved clinical outcomes. It has also initiated an early-stage proof-of-concept study of the candidate for CLE. A potentially registrational study to evaluate IMVT-1402 for SjD is also expected to begin in the summer of 2025. Immunovant is evaluating its second candidate, batoclimab, in ongoing mid-late-stage studies for two different autoimmune indications, GD and thyroid eye disease (TED). The company is gearing up to report new batoclimab proof-of-concept data for GD, including six-month treatment-free remission results, in summer 2025 to highlight IMVT-1402's potential. Top-line data from IMVT's late-stage TED study of batoclimab is expected to be shared in the second half of 2025, based on which IMVT will decide whether to file for regulatory approval. Immunovant, Inc. price-consensus-eps-surprise-chart | Immunovant, Inc. Quote Immunovant currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Bayer BAYRY, Lexicon Pharmaceuticals LXRX and Amarin AMRN, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. In the past 60 days, estimates for Bayer's earnings per share have increased from $1.19 to $1.25 for 2025. During the same time, earnings per share have increased from $1.28 to $1.31 for 2026. Year to date, shares of Bayer have gained 44.7%. BAYRY's earnings beat estimates in one of the trailing four quarters, matched twice and missed on the remaining occasion, the average negative surprise being 13.91%. In the past 60 days, estimates for Lexicon's loss per share have narrowed from 37 cents to 32 cents for 2025. During the same time, loss per share estimates for 2026 have narrowed from 35 cents to 31 cents. Year to date, shares of LXRX have lost 10.7%. LXRX's earnings beat estimates in three of the trailing four quarters and missed the same on the remaining occasion, delivering an average surprise of 11.97%. In the past 60 days, estimates for Amarin's loss per share for 2025 have narrowed from $5.33 to $3.48. During the same time, loss per share estimates for 2026 have narrowed from $4.13 to $2.67. Year to date, shares of AMRN have gained 20.4%. AMRN's earnings beat estimates in two of the trailing four quarters, matched once and missed the same on the remaining occasion, delivering an average surprise of 29.11%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report Lexicon Pharmaceuticals, Inc. (LXRX) : Free Stock Analysis Report Amarin Corporation PLC (AMRN) : Free Stock Analysis Report Immunovant, Inc. (IMVT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
